CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 148 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $417,331 | +36.8% | 27,990 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $304,958 | +548.8% | 27,850 | +83.0% | 0.00% | – |
| Q1 2022 | $47,000 | -7.8% | 15,220 | 0.0% | 0.00% | – |
| Q4 2021 | $51,000 | -7.3% | 15,220 | +1.2% | 0.00% | – |
| Q3 2021 | $55,000 | -16.7% | 15,045 | 0.0% | 0.00% | – |
| Q2 2021 | $66,000 | 0.0% | 15,045 | +3.1% | 0.00% | – |
| Q1 2021 | $66,000 | -21.4% | 14,594 | 0.0% | 0.00% | – |
| Q4 2020 | $84,000 | -20.8% | 14,594 | 0.0% | 0.00% | – |
| Q3 2020 | $106,000 | +107.8% | 14,594 | 0.0% | 0.00% | – |
| Q2 2020 | $51,000 | +183.3% | 14,594 | +20.0% | 0.00% | – |
| Q1 2020 | $18,000 | -25.0% | 12,164 | -2.0% | 0.00% | – |
| Q4 2019 | $24,000 | -62.5% | 12,414 | 0.0% | 0.00% | – |
| Q3 2019 | $64,000 | -28.1% | 12,414 | 0.0% | 0.00% | – |
| Q2 2019 | $89,000 | -45.1% | 12,414 | +1.5% | 0.00% | – |
| Q1 2019 | $162,000 | +68.8% | 12,234 | 0.0% | 0.00% | – |
| Q4 2018 | $96,000 | -28.4% | 12,234 | +1.2% | 0.00% | – |
| Q3 2018 | $134,000 | -7.6% | 12,090 | +11.8% | 0.00% | – |
| Q2 2018 | $145,000 | – | 10,810 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |